Skip to content

In the BioHarmony Drug Report Database

Ulipristal

Ella, Esmya (ulipristal) is a small molecule pharmaceutical. Ulipristal was first approved as Ella on 2010-08-13. It has been approved in Europe to treat leiomyoma. The pharmaceutical is active against progesterone receptor. Ella's patents are valid until 2030-06-12 (FDA).
Trade Name Esmya
Common Name Ulipristal
Indication leiomyoma
Drug Class Steriodal compounds acting on progesterone receptors (excluding -gest- compounds)
Ulipristal
Get full access now